Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M X Sliwkowski

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|January 1, 1988
Selenoprotein A of the clostridial glycine reductase complex: purification and amino acid sequence of the selenocysteine-containing peptideM X Sliwkowski, T C Stadtman
Current Oncology Reports|December 21, 2000
The biology of human epidermal growth factor receptor 2S Sundaresan, E Penuel, M X Sliwkowski
The Journal of Biological Chemistry|January 5, 1999
A discrete three-amino acid segment (LVI) at the C-terminal end of kinase-impaired ErbB3 is required for transactivation of ErbB2G Schaefer, R W Akita, M X Sliwkowski
Cancer Gene Therapy|December 23, 1999
Neuregulin receptor-mediated gene transfer by human epidermal growth factor receptor 2-targeted antibodies and neuregulin-1J A Kern, R Wakita, M X Sliwkowski
Oncogene|October 23, 1997
Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175G Schaefer, V D Fitzpatrick, M X Sliwkowski
FEBS Letters|April 24, 1999
Binding specificities and affinities of egf domains for ErbB receptorsJ T Jones, R W Akita, M X Sliwkowski
The Journal of Biological Chemistry|February 25, 1994
Genetically engineered proinsulin constitutively processed and secreted as mature, active insulinD J Groskreutz, M X Sliwkowski, C M Gorman
Seminars in Oncology|January 5, 2002
Structural requirements for ErbB2 transactivationE Penuel, G Schaefer, R W Akita, et al.
Cancer Research|June 5, 2001
A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4H Lee, R W Akita, M X Sliwkowski, et al.
Breast Disease|February 3, 2005
Development of herceptinP Carter, B M Fendly, G D Lewis, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Proceedings of the National Academy of Sciences of the United States of America|January 1, 1988
Selenoprotein A of the clostridial glycine reductase complex: purification and amino acid sequence of the selenocysteine-containing peptideM X Sliwkowski, T C Stadtman
Current Oncology Reports|December 21, 2000
The biology of human epidermal growth factor receptor 2S Sundaresan, E Penuel, M X Sliwkowski
The Journal of Biological Chemistry|January 5, 1999
A discrete three-amino acid segment (LVI) at the C-terminal end of kinase-impaired ErbB3 is required for transactivation of ErbB2G Schaefer, R W Akita, M X Sliwkowski
Cancer Gene Therapy|December 23, 1999
Neuregulin receptor-mediated gene transfer by human epidermal growth factor receptor 2-targeted antibodies and neuregulin-1J A Kern, R Wakita, M X Sliwkowski
Oncogene|October 23, 1997
Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175G Schaefer, V D Fitzpatrick, M X Sliwkowski
FEBS Letters|April 24, 1999
Binding specificities and affinities of egf domains for ErbB receptorsJ T Jones, R W Akita, M X Sliwkowski
The Journal of Biological Chemistry|February 25, 1994
Genetically engineered proinsulin constitutively processed and secreted as mature, active insulinD J Groskreutz, M X Sliwkowski, C M Gorman
Seminars in Oncology|January 5, 2002
Structural requirements for ErbB2 transactivationE Penuel, G Schaefer, R W Akita, et al.
Cancer Research|June 5, 2001
A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4H Lee, R W Akita, M X Sliwkowski, et al.
Breast Disease|February 3, 2005
Development of herceptinP Carter, B M Fendly, G D Lewis, et al.
Pageof 6